Comparative Pharmacology
Head-to-head clinical analysis: RIOCIGUAT versus VERQUVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIOCIGUAT versus VERQUVO.
RIOCIGUAT vs VERQUVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the nitric oxide (NO) signaling pathway, by sensitizing sGC to endogenous NO and directly stimulating sGC independently of NO. This increases intracellular cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation and inhibition of platelet aggregation.
Vericiguat stimulates soluble guanylate cyclase (sGC) directly and independently of nitric oxide (NO), increasing cyclic guanosine monophosphate (cGMP) production, leading to smooth muscle relaxation, vasodilation, and inhibition of platelet aggregation and vascular remodeling.
1 mg orally three times daily for 2 weeks, then increase by 0.5 mg every 2 weeks to target maintenance dose of 2.5 mg three times daily, as tolerated.
Initial: 10 mg orally once daily; after 2 weeks, titrate to 20 mg once daily, then to 40 mg once daily as tolerated. Maximum: 40 mg once daily.
None Documented
None Documented
Clinical Note
moderateRiociguat + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Riociguat."
Clinical Note
moderateRiociguat + Methylphenidate
"Riociguat may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateRiociguat + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Riociguat."
Clinical Note
moderateRiociguat + Erythromycin
Terminal elimination half-life is approximately 7 hours (range 5-12 hours) in patients with pulmonary arterial hypertension. In healthy subjects, half-life is about 5-7 hours. Steady state is achieved within 3-5 days of twice-daily dosing.
Terminal elimination half-life is approximately 22 hours (range 18-26 h), supporting once-daily dosing. Steady-state reached within 5 days.
Primarily hepatic metabolism, with minimal renal excretion. Approximately 50-60% of the dose is excreted in feces as metabolites, and about 40-50% in urine as metabolites (4-9% unchanged in urine). Biliary excretion of parent drug is negligible.
Renal elimination accounts for approximately 70% of total clearance, with 30% excreted unchanged in urine; biliary/fecal elimination accounts for ~30% primarily as metabolites.
Category C
Category C
Guanylate Cyclase Stimulator
Guanylate Cyclase Stimulator
"The metabolism of Erythromycin can be decreased when combined with Riociguat."